Acorn AI Intelligent Trials Webcast

Watch On Demand

COVID-19 and Clinical Trials: Support Risk Mitigation and Recovery Plans With Data and Analytics

As COVID-19 continues to spread and countries restrict movement, the impact on clinical trials is unmistakable. New studies are being delayed, and patients already enrolled in trials are facing challenges making their scheduled visits. Sponsors and CROs are trying to assess the impact on their studies, mitigate risk, and develop recovery plans. This webinar will address key considerations for managing clinical trials during these turbulent times and will highlight how industry-wide trial metrics and analytics can support:

  • Situation tracking by geography and therapeutic area
  • Impact assessments and scenario analyses at trial and portfolio level
  • Identification of leading indicators of recovery

Featured Speakers

Jef Benbanaste
Product Lead, Intelligent Trials
Acorn AI, a Medidata Company

Jef has led the launch and commercialization of multiple analytical SaaS offerings at Medidata and currently heads Intelligent Trials. Jef has over 15 years of experience improving business processes and decision-making through the use of technology and analytics. Prior to joining Medidata, Jef led projects at AIG which applied predictive modeling and machine learning techniques to improve risk segmentation and shape business unit strategies. He has a MBA from MIT and a BS from the University of Virginia.

Rachel Horovitz
Senior Director, Product Strategy
Acorn AI, a Medidata Company

Rachel leads Acorn AI’s newly launched Trial Impact Analytics offering, which helps companies navigate the evolving COVID-19 environment and inform critical recovery planning decisions. Prior to this role, she was the Head of Strategic Initiatives and led the launch of the Medidata Institute. Before joining Medidata, Rachel spent several years at Bain & Co. and Rothschild, advising healthcare and technology companies on strategic issues and decisions. She holds a Master in Biomedical Engineering from the University of Bern in Switzerland, an MBA from the MIT Sloan School of Management and a BS in Economics from The Wharton School, University of Pennsylvania.